AKS-452 is a biologically-engineered vaccine comprising an Fc fusion protein of the SARS-
CoV-2 viral spike protein receptor binding domain antigen (Ag) and human IgG1 Fc …

The novel coronavirus SARS-CoV-2 has infected more than 104 million individuals and
resulted in more than 2.2 million deaths worldwide as of February 7, 2021 (https://covid19 …

The development of an effective vaccine against SARS-CoV-2 is urgently needed. We
generated SARS-CoV-2 RBD-Fc fusion protein and evaluated its potency to elicit …

Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), which is a novel subset of coronavirus. To this day, the …

Background Heterologous boost vaccination has been proposed as an option to elicit
stronger and broader, or longer-lasting immunity. We assessed the safety and …

The development of safe and effective vaccines to respond to COVID-19 pandemic/endemic
remains a priority. We developed a novel subunit protein-peptide COVID-19 vaccine …

Waning of neutralizing titres along with decline of protection efficacy after the second dose of
COVID-19 vaccines was observed, including China-made inactivated vaccines. Efficacy of a …

Herein, we report that a recombinant fusion protein, containing a 457 amino acid SARS-CoV-
2 receptor binding domain (RBD, residues 319–541) and a mouse IgG1 Fc domain, could …

Background Previous interim data from a phase I study of AKS-452, a subunit vaccine
comprising an Fc fusion of the respiratory syndrome coronavirus 2 (SARS-CoV-2) spike …

Summary Background The SARS-CoV-2 global pandemic has fuelled the generation of
vaccines at an unprecedented pace and scale. However, many challenges remain …